Vivos Therapeutics (VVOS)

• Market cap: $24.1M
• 1 day: 6.87%
• 5 days: 0.20%
• 1 month: 72.32%
• 3 months: 61.69%
• 6 months: 109.24%
• Year to date: -57.80%
• 1 year: -58.98%
• 5 years: -97.78%
• 10 years: -97.78%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Employees: 114

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

45% more capital invested

Capital invested by funds: $434K [Q2] → $631K (+$197K) [Q3]

21% more funds holding

Funds holding: 19 [Q2] → 23 (+4) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.36% less ownership

Funds ownership: 5.5% [Q2] → 5.14% (-0.36%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 20% upside
• Avg. target: $6.30 27% upside
• High target: $6.60 33% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Lucas Ward 33% 1-year accuracy 4 / 12 met price target	33% upside $6.60	Buy Reiterated	20 Nov 2024
Alliance Global Partners Scott Henry 60% 1-year accuracy 3 / 5 met price target	20% upside $6	Buy Maintained	19 Nov 2024